CRC Credit Research Compendium
Menu

Issuer Credit Research

Great Eastern Life Issuer Flash: 1H 2026 Results

Issuer: Great Eastern Life | Document: Issuer Flash | Date: 2026-08-03 | Event: 1h 2026 Results

Report date: 2026-08-03 Event date: 2026-07-31 Event title: 1H 2026 Results

Flash Conclusion

Great Eastern Holdings Limited's (GEH) 1H-26 results provide a positive confirmation of the operating and financial context supporting The Great Eastern Life Assurance Company Limited (GEL). The group reported materially higher new-business value, insurance-business profit and profit attributable to shareholders, while group equity increased despite interim shareholder distributions. The results therefore reinforce, rather than change, the latest view that GEL has a high-quality and broadly stable credit profile within the GEH/OCBC insurance franchise.

The read-through is not an issuer-level capital upgrade. The disclosed figures are GEH consolidated and the interim financial statements are unaudited; GEL standalone financial statements, regulatory-capital ratios and capital headroom were not provided. Profit also benefited from stronger equity-market performance and from reversal of losses on onerous contracts. Those factors support the reported outcome, but they do not by themselves establish that medical-claims, lapse, reinsurance or product-profitability risks have structurally receded. For GEL bondholders, the key constraints remain the interaction of long-duration insurance liabilities with investment-market movements, the lack of standalone capital disclosure, and the potential instrument-specific ranking, loss-absorption and payment risks that require confirmation from final AT1 and Tier 2 documentation.

What Was Announced

On 31 July 2026, GEH released unaudited consolidated results for the half year ended 30 June 2026. New business was led by Singapore, with 1H-26 Singapore TWNS up 20% year on year and Malaysia up 5%. GEH stated that the higher NBEV reflected higher sales and a more favourable product mix. The group also declared a 35 Singapore-cent interim dividend per GEH share, payable on 28 August 2026.

GEH consolidated income / new-business metric (S$mn) 1H-26 1H-25 YoY
Total Weighted New Sales 813.2 708.6 +15%
New Business Embedded Value 405.3 316.5 +28%
Profit from insurance business 615.3 415.2 +48%
Profit from shareholders' fund 234.2 178.5 +31%
Profit attributable to shareholders 849.5 593.7 +43%
Other comprehensive income 87.3 167.3 -48%
Total comprehensive income 936.8 761.0 +23%
GEH consolidated balance-sheet metric (S$mn) 30 Jun 2026 31 Dec 2025 Change vs. 31 Dec 2025
Total equity 11,118.9 10,473.1 +6%
Insurance contract liabilities 106,677.7 107,792.1 -1%
Investments 108,912.2 108,970.9 broadly stable

The statutory result reported an insurance service result of S$808.9mn, up 32%, which GEH attributed largely to reversal of losses on onerous contracts. Other investment revenue rose 85% to S$3,126.1mn, mainly due to favourable equity-market performance. Conversely, the net insurance financial result was a S$3,993.2mn loss, versus a S$2,686.4mn loss in 1H-25, mainly because of fair-value movements in underlying items for contracts with direct participation features.

Credit Read-Through

The new-business data are supportive of franchise strength. TWNS rose 15% and NBEV rose faster, by 28%, with the company attributing the latter to a more favourable product mix as well as higher sales. That trend is consistent with the 1Q-26 flash's view that the franchise remained intact, and Singapore's 20% TWNS growth suggests that the principal market continued to provide the main momentum. NBEV is a measure of expected long-term profitability of new sales, however; it is not the same as immediately available cash or regulatory capital and should not be read as a direct measure of GEL debt-service capacity.

Profitability was stronger across the headline measures, and accumulated group equity increased to S$11.1bn from S$10.5bn at year-end even after S$284.0mn of ordinary dividends and S$17.3mn of distributions on perpetual capital securities paid during the first half. This is a favourable group-level capital-formation signal. It remains necessary to distinguish it from GEL legal-entity capital: the release says only that the capital-adequacy ratios of the group insurance subsidiaries in Singapore and Malaysia are strong and well above minimum regulatory levels. It provides neither GEL's numerical capital ratio nor the available-capital and required-capital components.

Earnings quality remains mixed in a way that is normal for a life insurer with large investment assets and long-duration liabilities. The S$615.3mn insurance-business profit was supported by in-force earnings emergence, positive underlying experience and reserve releases, but the statutory result also benefited from stronger equity performance. Meanwhile, OCI declined 48% year on year and the group disclosed continuing exposure to fluctuations in interest rates, credit spreads and equity prices. The smaller 1H-26 OCI reflects bond mark-to-market losses in a less favourable interest-rate environment, partly offset by equity gains. The credit implication is not a near-term stress signal; rather, it confirms that profitability, reported comprehensive income and capital need to be assessed through asset-liability interactions rather than from headline earnings alone.

The 30 June balance sheet is consistent with that conclusion. GEH reported S$108.9bn of investments and S$106.7bn of insurance contract liabilities, each broadly unchanged from year-end, while total equity increased by 6%. For the Singapore life funds excluding investment-linked funds, fixed income and debt securities were 50% of market value, equities 39%, real estate and other assets 7%, and cash and money-market instruments 4%. This is not sufficient to assess duration matching or asset credit quality, but it illustrates why interest rates, credit spreads and equity valuations can affect the insurer's financial statements in different channels. Changes in fair value of assets may be partly offset by measurement changes in direct-participation liabilities, but the net result, OCI and regulatory capital can still move materially. The reported reduction in the adverse insurance-finance reserve impact from yield-curve changes is encouraging, without eliminating that sensitivity.

The period also makes the distinction between ordinary shareholder distributions and creditor protection important. GEH's 35-cent interim dividend is paid by the listed parent and is guided by its sustainable-profit policy; it is not a distribution from GEL nor evidence that capital is freely transferable between regulated entities. Likewise, the S$17.3mn first-half distribution on perpetual capital securities appears in the GEH consolidated statement of changes in equity, but the disclosure does not supply the legal-entity capital analysis needed to assess future GEL AT1 distributions. No adverse capital action is disclosed, and the group says subsidiary capital ratios remain well above regulatory minima. The appropriate conclusion is a positive group-level capital-formation and qualitative regulatory-compliance signal, accompanied by a material information limitation at the GEL issuing-entity level.

The interim dividend is consistent with GEH's stated progressive, sustainable-profit approach, and there is no disclosed indication that it impaired regulatory compliance. Nevertheless, it is a shareholder-level distribution rather than evidence of an entitlement for GEL creditors. Nor do the results alter the structural assessment of GEL capital securities: the existing reports have not obtained the final transaction documents needed to assess the relevant payment, loss-absorption, call and ranking provisions. OCBC's strategic relationship with GEH remains support context, not an explicit guarantee of GEL obligations.

What To Watch Next

The next result should be used to test whether new-business value continues to outpace sales without an adverse shift in guarantees, capital consumption or medical-product risk. More importantly, investors should seek detail on the drivers and sustainability of the onerous-contract loss reversal, medical claims, repricing, lapse experience, reinsurance and CSM movements before treating the higher insurance profit as a structural change.

At the issuer level, confirmation of GEL standalone audited financials and MAS capital data remains the most useful step to improve precision. Monitoring should also cover investment-portfolio credit quality, duration and hedging; the impact of interest rates, credit spreads and equities on OCI and capital; and the effect of GEH shareholder distributions and any further capital issuance on group and entity-level buffers. For AT1 and Tier 2 investors, final offering documents, current instrument ratings and market pricing remain necessary before reaching conclusions on instrument-specific payment, call, loss-absorption, ranking or relative-value considerations.

Sources

Unverified / Pending